However, treatment of CML with herbamycin A, also a tyrosine kinase inhibitor, was found to be ineffective in TERT suppression, which is likely due to the compensatory effects of TERT regulators. This evidence concerns the gene TERT and chronic myelogenous leukemia, BCR-ABL1 positive.